The application of umbilical cord blood is a relatively advanced technology, and after more than 30 years of tempering, this technology has become more and more mature now, and because of this, it has also brought more new hope to the clinical field.
Studies have found that umbilical cord blood hematopoietic stem cell transplantation can be used in hematologic diseases and immune system diseases, and has been found to be used in more than 80 diseases, including the more common malignant tumors and leukemia. Leukemia is a blood disease that is common in children, and relevant data show that the number of children with leukemia in China continues to increase every year, which has aroused great concern in the society. As parents, we all want our children to grow up healthy and don't want them to suffer from illness. But when the risk of disease comes, what we can do is to face it aggressively and courageously and find new solutions. However, the traditional regimen** is very difficult, and the advent of cord blood hematopoietic stem cell transplantation has provided a new option for these families.
Researchers have further promoted the application of umbilical cord blood and combined it into the clinical scenario of leukemia**, and further determined the positive significance of umbilical cord blood hematopoietic stem cell transplantation in the process of leukemia** through clinical trials again and again. After a long period of research and analysis, researchers have found that hematopoietic stem cells in umbilical cord blood can help the human body rebuild the blood system, provide a new direction for leukemia, and also bring hope for rebirth for children and their families.
In further research on the application of umbilical cord blood, it was found that there are more advantages to leukemia through this program, such as less leukemia, less cost of transplantation, higher success rate and so on. Autologous umbilical cord blood is self-administered without rejection, graft-versus-host disease, cell number and survival, and no tumor contamination.
It is precisely because there is a broader space in hematologic diseases, so modern medical experts attach great importance to the application of umbilical cord blood hematopoietic stem cell transplantation, and more new results are expected to appear by increasing investment in the future. And the implementation of each new achievement will be a hope of rebirth for those patients and their families who are battling the disease.